ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1146

Characteristics of Malignancy in Kidney Transplant Recipients at the Keck Hospital of USC in Year 2006 Through 2009 Compared to Year 2000 Through 2004

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical


  • Azimi, Roshanak, Keck School of Medicine of USC, Los Angeles, California, United States
  • Kwon, Osun, Keck School of Medicine of USC, Los Angeles, California, United States

Recent national kidney transplant registry data reported that 17 % reported causes of death are due to malignancy after transplant, which suggests higher incidence of malignancy as a cause of death compared to 13% about a decade ago.


The study has been conducted by reviewing medical records of kidney transplant recipients who had been followed by the transplant team at Keck Hospital of USC in 2000 through 2019. The findings have been compared in 200 patients who had received a kidney transplant in two time periods; 100 patients each in 2000 through 2004 (group 1) and 2006 through 2009 (group 2) and had at least 10 years of follow-up.


Subjects (83 female, 116 male) were 134 recipients of a kidney transplant from a deceased donor and 66 from a living donor. Mean age of patients at the time of the first kidney transplant was 48 (range 17-77) and 48 (range 23-75) in group 1 and group 2. Hispanic is the majority followed by Caucasian, Asian, African American; 56, 22, 13, 3% in group 1 and 52, 19, 21, 7%, respectively in group 2.
In group 1, 14 patients developed malignancy after kidney transplant; 8 within 10 years post-transplant. In group 2, 12 patients were diagnosed with malignancy; 11 within 10 years.
In group 1, 32 patients died and in group 2, 25 patients died. Seven died with functioning graft in group 1 (22% of mortality) and 5 died with functioning graft in group 2 (20% of mortality).
Types of cancers were variable; adenocarcinoma of lung, GI and prostate, squamous cell carcinoma of the skin, lymphoma, and thyroid cancer. In group 2, HCC was in 4 among 12 reported malignancies. HCC was diagnosed in 3 recipients of combined liver and kidney transplant.
In group 1, 15 patients received induction immunosuppression (OKT3, Thymoglobulin, Basiliximab/Daclizumab), while in group 2, 69 patients received Thymoglobulin or Basiliximab.
Duration until the time of cancer diagnosis after transplant seems shortened considerably; median and mean time, 4 and 6.9 years in group 1 vs. 2.4 and 2.7 years in group 2, respectively.


In kidney transplant recipients who received a kidney transplant in 2006-2009, incidence of cancer seems increased during 10 year follow-up and duration until the time of cancer diagnosis seems shortened, compared to those in 2000 through 2004, in the patient population studied.